t
On 31 July 2026, Thalia Therapeutics plc announced its total voting rights. For the purposes of the FCA's Disclosure and Transparency Rules, the company stated that its total issued share capital consists of 1,775,720,897 ordinary shares of 0.4 pence each, all carrying voting rights.
| Date | 31 Jul 2026 |
| Time | 11:07:26 |
| Category | Capital structure |
| ID | 7812O |
31 July 2026
Thalia Therapeutics plc
("Thalia" or the "Company")
Total Voting Rights
Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces, for the purposes of the FCA's Disclosure and Transparency Rules, that the total issued share capital of the Company consists of 1,775,720,897 ordinary shares of 0.4 pence each with voting rights.
The above figure may be used by shareholders as the denominator in calculations to determine whether they are required to notify their interest in, or a change in their interest in, the share capital of the Company.
- Ends -
For more information please contact:
|
Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer |
Via Thalia Investor Hub |
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/Guy McDougall |
Tel: +44 (0)20 3657 0050 |
|
Northstar Communications Limited Investor relations and Communications Sarah Hollins
Cohesion Bureau Investor relations and Communications Mary-Ann Chang |
Tel: +44 (0)20 7183 2463
Tel: +44 (0)7483 284853
|
About Thalia Therapeutics plc
Thalia Therapeutics is a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies across oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat disease at its source by silencing or modifying the genes that cause or contribute to it.
Our clinical-stage programme miRisten is a microRNA therapeutic in development for Acute Myeloid Leukaemia (AML). Alongside this, our preclinical bispecific siRNA programme is being developed as a potentially long-acting treatment for atherosclerotic cardiovascular disease by addressing two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec®, offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.
For further information visit www.thaliatx.com